Novo Nordisk Presents New Wegovy Data for Women with Obesity at European Congress on Obesity 2026

Key Takeaways

• Novo Nordisk will present new clinical data and real-world evidence on Wegovy at the European Congress on Obesity, May 12-15 in Istanbul
• The presentations will focus specifically on Wegovy’s effectiveness in women with obesity and showcase next-generation weight loss treatments
• Wegovy is currently approved by FDA as both daily pills and weekly injections, while EMA has approved weekly injection formulations

---

BAGSVÆRD, Denmark – Novo Nordisk announced it will present new clinical data and real-world evidence on its blockbuster weight loss drug Wegovy at the European Congress on Obesity, taking place May 12-15, 2026, in Istanbul, Turkey.

The Danish pharmaceutical giant will showcase findings specifically related to Wegovy’s performance in women with obesity, addressing a critical patient population that has historically been underrepresented in obesity treatment research. The company will also present data on its next-generation weight loss treatments, signaling continued innovation in the rapidly expanding obesity therapeutics market.

Regulatory Landscape and Market Position

Wegovy (semaglutide) has established itself as a leading treatment for chronic weight management. The FDA has approved multiple formulations, including a once-daily oral tablet (25 mg) and weekly injections available in 1.7 mg, 2.4 mg, and 7.2 mg doses. European regulators have approved the weekly injection formulations at 2.4 mg and 7.2 mg strengths.

The focus on women with obesity represents a significant development, as this demographic faces unique challenges in weight management due to hormonal factors, metabolic differences, and varying treatment responses compared to men.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Implications

The presentation of new data at this prestigious European obesity conference underscores Novo Nordisk’s commitment to expanding the evidence base for Wegovy while maintaining its competitive edge in the obesity treatment market. With obesity rates continuing to rise globally, particularly among women, these findings could influence treatment guidelines and expand Wegovy’s market penetration.

The mention of next-generation treatments suggests Novo Nordisk is preparing for future competition while building on Wegovy’s current success. This strategic approach positions the company to maintain market leadership as the obesity therapeutics landscape evolves.

---

Frequently Asked Questions

What new data will Novo Nordisk present about Wegovy?

Novo Nordisk will present new clinical data and real-world evidence specifically focused on Wegovy’s effectiveness in women with obesity, plus information about next-generation weight loss treatments.

When and where is the European Congress on Obesity taking place?

The European Congress on Obesity will be held May 12-15, 2026, in Istanbul, Turkey, where Novo Nordisk will present their latest Wegovy research findings.

What Wegovy formulations are currently approved?

The FDA has approved Wegovy as both a once-daily 25 mg tablet and weekly injections (1.7 mg, 2.4 mg, 7.2 mg), while the EMA has approved weekly injections at 2.4 mg and 7.2 mg doses.

Related coverage

• Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting
• Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications
• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data